|[July 23, 2014]
Personalized Chemotherapy Tests Cleared for Use in China
SHANGHAI & BETHLEHEM, Pa. --(Business Wire)--
Fosun Diagnostics, a division of Fosun Pharmaceuticals, and Saladax
Biomedical, Inc. today announced the launch of the MyCare™ portfolio of
exposure optimization tests in China. Saladax Biomedical develops and
markets MyCare diagnostic tests designed to customize chemotherapy
dosing for patients. Fosun Diagnostics is Saladax's manufacturing,
clinical and market development partner in China for the entire MyCare
MyCare assays are blood tests that provide oncologists with specific
information about each patient's exposure to a chemotherapy drug,
helping the doctor to make informed decisions on dose adjustments. The
goal of each blood test is to maximize the chemotherapy's effectiveness
and limit potential side effects. MyCare is built upon the Saladax
technology platform and extensive patent portfolio.
"China has a long established history of personalized medicine and these
assays will give our healthcare providers a way to manage each patient
individually, thereby allowing for the best possible outcomes as they
battle cancer," said Ted Zhu, CEO of Fosun Diagnostics Division. "Our
invesment in, and partnership with Saladax, was for the specific
purpose of bringing this kind of personalized cancer care to the people
of China and we are pleased to begin making these diagnostic tests
Fosun received CFDA clearance to market three MyCare assays - My5-FU™,
MyPaclitaxel™, and MyDocetaxel™. Fosun will manage distributors and will
work directly with large healthcare facilities and oncologists to make
this technology available to the large Chinese market. Fosun imported
the technology from Saladax Biomedical, Inc. and it is currently
CE-marked. At present, these products are in clinical use in the United
States, Japan, and Europe.
"The launch of Saladax's MyCare tests in China represents an important
milestone for Saladax," said Kevin M. Harter, President and CEO of
Saladax. "Fosun has been an excellent business partner in all respects,
and we have high expectations for this market."
The MyCare technology platform and product portfolio are in a leading
position in the world. Through continuous product research and
development, the portfolio can cover up to 80%-90% of the routine
anti-tumor drug monitoring market. Fosun Diagnostics will maintain close
cooperation with Saladax and develop more of the anti-tumor drug tests
to meet the market demand in China.
About Saladax Biomedical, Inc.
Saladax Biomedical is a leader in the development and deployment of
high-quality diagnostic services and products, delivering actionable
data to help physicians to select and optimize the use of current and
new pharmaceutical products, with the goals of improving health and
positively impacting the economics of care… because no two patients are
Headquartered in Bethlehem, Pennsylvania, Saladax was founded in 2004
and is ISO 13485:2003 certified.
Fosun Pharma, based in Shanghai, is a leading healthcare company in
China. Established in 1994, it has been listed on Shanghai Stock
Exchange since August 1998. Fosun Pharma develops, produces and
distributes pharmaceuticals, healthcare services, diagnostic products
and medical devices.
[ Back To TMCnet.com's Homepage ]